Immune signature of patients with cardiovascular disease predicts increased risk for a severe course of COVID‐19
European Journal of Immunology · 2024
DOI: 10.1002/eji.202451145 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2024. Verfasst von Manina Günter und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebing…. Hauptthemen laut MEDLINE: COVID-19, Cardiovascular Diseases, SARS-CoV-2, Killer Cells, Natural. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: German Research Foundation (DFG), Ministry of Science, Research and the Arts of the State of Baden-Württemberg: Long-COVID Funding.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus type 2 (SARS‐CoV‐2) infection can lead to life‐threatening clinical manifestations. Patients with cardiovascular disease (CVD) are at higher risk for severe courses of COVID‐19. So far, however, there are hardly any strategies for predicting the course of SARS‐CoV‐2 infection in CVD patients at hospital admission. Thus, we investigated whether this prediction is achievable by prospectively analysing the blood immunophenotype of 94 nonvaccinated participants, including uninfected and acutely SARS‐CoV‐2‐infected CVD patients and healthy donors, using a 36‐colour spectral flow cytometry panel. Unsupervised data analysis revealed little differences between healthy donors and CVD patients, whereas the distribution of the cell populations changed dramatically in SARS‐CoV‐2‐infected CVD patients. The latter had more mature NK cells, activated monocyte subsets, central memory CD4 + T cells, and plasmablasts but fewer dendritic cells, CD16 + monocytes, innate lymphoid cells, and CD8 + T‐cell subsets. Moreover, we identified an immune signature characterised by CD161 + T cells, intermediate effector CD8 + T cells, and natural killer T (NKT) cells that is predictive for CVD patients with a severe course of COVID‐19. Thus, intensified immunophenotype analyses can help identify patients at risk of severe COVID‐19 at hospital admission, improving clinical outcomes through specific treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.
- German Cancer Research Centre, Research Group Dendritic Cells in Infection and Cancer, Heidelberg, Germany.
- Department of Cardiology and Angiology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.
ORCID-Profile: Stella E Autenrieth
Förderung
- German Research Foundation (DFG)
- Ministry of Science, Research and the Arts of the State of Baden-Württemberg: Long-COVID Funding
Zitieren
APA
Günter, M., Mueller, K. A. L., Salazar, M. J., Gekeler, S., Prang, C., Harm, T., Gawaz, M. P., & Autenrieth, S. E. (2024). Immune signature of patients with cardiovascular disease predicts increased risk for a severe course of COVID‐19. European Journal of Immunology. https://doi.org/10.1002/eji.202451145
Vancouver
Günter M, Mueller KAL, Salazar MJ, Gekeler S, Prang C, Harm T, et al. Immune signature of patients with cardiovascular disease predicts increased risk for a severe course of COVID‐19. European Journal of Immunology. 2024. doi:10.1002/eji.202451145
BibTeX
@article{Gnter2024,
author = {Günter, Manina and Mueller, Karin Anne Lydia and Salazar, Mathew J and Gekeler, Sarah and Prang, Carolin and Harm, Tobias and Gawaz, Meinrad Paul and Autenrieth, Stella E},
title = {Immune signature of patients with cardiovascular disease predicts increased risk for a severe course of COVID‐19},
journal = {European Journal of Immunology},
year = {2024},
doi = {10.1002/eji.202451145}
}
EUVIMED